because our probody therapeutics are designed to minimize binding of potent anti-cancer therapy to normal tissues , we believe we can address a new class of targets with attractive molecular features that were previously unsuitable because of high expression on normal tissues . cd166 is an example of this kind of target . cd166 is highly and homogenously expressed in multiple different tumors types , which makes it an attractive target for a probody drug conjugate therapeutic ; however , the high expression of cd166 on normal tissues makes this a difficult target to drug with a traditional adc . cx-2009 is currently in the dose escalation portion of a phase 1/2 study . in february 2019 , we disclosed initial clinical data on cx-2009 at the cytomx r & d day . in addition to our wholly owned programs , we have entered into several strategic collaborations with leading oncology-focused pharmaceutical companies , such as abbvie inc. , through its subsidiary abbvie ireland unlimited company ( “ abbvie ” ) , amgen , inc. ( “ amgen ” ) and bristol-myers squibb company ( “ bms ” ) . the most advanced program from our partnerships is a bms-986249 , a ctla-4 probody therapeutic , which bms is currently advancing through the dose escalation phase of a phase 1/2 clinical trial . we are also treating patients in a phase 1/2 clinical study for cx-2029 , a pdc targeting the highly expressed target , cd71 that we have partnered with abbvie . we have also extended our probody platform to the t-cell engaging bispecific modality . our most advanced program in that modality is an epidermal growth factor receptor-cd3 ( “ egfr-cd3 ” ) t-cell bispecific , which is currently in lead optimization stage , and which we are developing in partnership with amgen . we currently have three product candidates enrolling patients in clinical trials that we are conducting and one product candidate enrolling patients in clinical trials which our partner , bms , is conducting , but we do not have any product candidates approved for sale , and we continue to incur significant research and development and general administrative expenses related to our operations . we are not profitable and have incurred losses in each year since our founding in 2008. our net loss was $ 84.6 million , $ 43.1 million and $ 58.9 million for 2018 , 2017 and 2016 , respectively . as of december 31 , 2018 and 2017 we had an accumulated deficit of $ 315.0 million and $ 219.5 million , respectively . we expect to continue to incur significant losses for the foreseeable future . 77 regulatory agencies , including the fda , regulate many aspects of a product candidate 's life cycle , including research and development and preclinical and clinical testing . we will need to commit significant time , resources , and funding to develop our wholly owned and partnered product candidates in clinical trials , including cx-072 , cx-2009 and cx-2029 as well as any additional product candidates for which we initiate clinical trials in 201 9 and beyond . we are unable to provide the nature , timing , and estimated costs of the efforts necessary to complete the development of our product candidates because , among other reasons , of regulatory uncertainty , manufacturing limitations and the pace of enrollment of our clinical trials , which is a function of many factors , including the availability and proximity of patients with the relevant condition . we currently have no manufacturing capabilities and do not intend to establish any such capabilities in the near term . as such , we are dependent on third parties to supply our product candidates according to our specifications , in sufficient quantities , on time , in compliance with appropriate regulatory standards and at competitive prices . components of results of operations revenue our revenue to date has been primarily derived from non-refundable license payments , milestone payments and reimbursements for research and development expenses under our research , collaboration , and license agreements . we recognize revenue from upfront payments over the term of our estimated period of performance under the agreement using a cost-based input method or a common measure of progress for the entire performance obligation . in addition to receiving upfront payments , we may also be entitled to milestone and other contingent payments upon achieving predefined objectives . revenue from milestones and other contingent payments , when it is probable that there will not be a significant revenue reversal , is also recognized over the performance period based on a similar method . reimbursements from bms and pfizer for research and development costs incurred under our research , collaboration and license agreements with them are classified as revenue . for the foreseeable future , we do not expect to generate any revenue from the sale of products unless and until such time as our product candidates have advanced through clinical development and obtained regulatory approval . we expect that any revenue we generate in the foreseeable future will fluctuate from year to year as a result of the timing and amount of milestones and other payments from our collaboration agreements with abbvie , amgen , bms , immunogen and any other collaboration partners , and as a result of the fluctuations in the research and development expenses we incur in the performance of assigned activities under these agreements . abbvie ireland unlimited company ( “ abbvie ” ) , one of our collaboration partners , entered into a license agreement with seattle genetics , inc. ( “ sgen ” ) to license certain intellectual property rights . as part of our collaboration agreement with abbvie , we pay sgen sublicense fees . these sublicense fees are treated as reductions to the transaction price and combined with the performance obligation to which they relate . story_separator_special_tag 82 comparison of years ended december 31 , 2017 and 2016 revenue year ended december 31 , 2017 2016 change ( in thousands ) revenue $ 71,623 $ 15,043 $ 56,580 revenue increased $ 56.6 million during the year ended december 31 , 2017 compared to the corresponding period in 2016. the following table summarizes our revenue by collaboration partner during the respective periods : replace_table_token_7_th the increase in revenue from abbvie of $ 16.2 million for the year ended december 31 , 2017 compared to the corresponding period in 2016 was due to recognition of $ 14.0 million , net of the associated sublicense fee , from the milestone payment we received as a result of our achievement of certain milestones required to be met to begin glp toxicology studies under the abbvie agreements , and an increase of $ 2.2 million , net of the related deferred costs , related to the recognition of the upfront payment we received in april 2016. we entered into the amgen agreement in september 2017 and we recognized $ 1.3 million of upfront payments in 2017. the increase in revenue from bms of $ 26.9 million for the year ended december 31 , 2017 compared to the corresponding period in 2016 was due to an increase of $ 17.1 million related to the recognition of an upfront payment we received in connection with the expansion of our collaboration , an increase of $ 2.1 million related to the recognition of payments made in connection with the selection of its fourth target under our collaboration and license agreement with bms and the acceleration of the research timeline triggered by bms 's selection of a fourth target under the bms agreement , and a milestone payment of $ 10.0 million related to the ind filing for bms-986249 by bms in 2017. these increases were partially offset by a milestone payment of $ 2.0 million payment received in 2016 for the selection of bms-986249 clinical candidate , and a decrease of $ 0.3 million related to research and development services provided to bms . the increase in revenue from immunogen of $ 12.5 million for the year ended december 31 , 2017 compared to the corresponding period in 2016 was a result of the recognition of $ 6.6 million for the delivery of the immunogen 2017 license to immunogen in connection with the immunogen research agreement and the recognition of $ 5.9 million resulting from an amendment to the immunogen research amendment . see note 9 - research and collaboration agreements under item 8 of this annual report on form 10-k for more details . the decrease in revenue from pfizer of $ 0.3 million for the year ended december 31 , 2017 compared to the corresponding period in 2016 was due to a reduction in the research and development services we provided to pfizer . in march 2018 , pfizer gave notice terminating our collaboration in its entirety . as a result of such termination , we are no longer eligible to receive any future payments from our collaboration with pfizer . research and development expenses year ended december 31 , 2017 2016 change ( in thousands ) research and development $ 92,277 $ 54,755 $ 37,522 83 research and development expenses increased $ 37.5 million during the year ended december 31 , 2017 compared to the corresponding period in 2016. the increase was primarily attributable to the following : a non-cash charge of $ 10.7 million of in-process research and development expense recognized related to the amgen agreement ; $ 10.0 million sublicense payment made to ucsb triggered by the $ 200.0 million upfront payment made by bms in connection with our expanded collaboration ; $ 2.1 million of ucsb sublicense fees accrued as a result of the amgen agreement ; $ 1.0 million of ucsb sublicense fees recognized for our achievement of certain milestones required to be met to begin glp toxicology studies under the abbvie agreement and the ind filing for bms-986249 by bms ; an increase of $ 8.5 million in pharmacology studies and clinical trial expenses resulting from the advancement of cx-072 , cx-2009 and cx-2029 in 2017 ; an increase of $ 5.3 million in personnel-related expenses and allocation of it and facilities-related expenses due to an increase in headcount ; an increase of $ 1.7 million in consulting expenses due to the commencement of clinical trials in 2017 ; an increase of $ 0.6 million related to expenses incurred in acquiring a patent ; and an increase of $ 0.5 million in stock-based compensation resulting from increased headcount and an increase in the value of our stock . these increases were partially offset by : a decrease of $ 2.1 million in manufacturing expenses for our cx-072 and cx-2009 programs due to manufacturing activities occurring in 2016 in preparation for clinical trials in 2017 ; a decrease in laboratory supply expenses of $ 0.4 million ; and a decrease in program management expenses of $ 0.4 million . the following table summarizes our research and development expenses by program incurred during the respective periods : replace_table_token_8_th general and administrative expenses year ended december 31 , 2017 2016 change ( in thousands ) general and administrative $ 25,605 $ 19,874 $ 5,731 84 general and administrative expense increased $ 5.7 million during the year ended december 31 , 2017 compared to the corresponding period in 2016. the increase was attributable to an increase of $ 1.4 million in personnel-related expenses and an increase of $ 1.0 million in recruitment fees due to an increase in headcount and temporary labor ; an increase in stock-based compensation of $ 1.0 million due to an increase in headcount and an increase in the value of our stock ; an increase of $ 1.2 million in consulting services expenses primarily due to an increase in tax and accounting compliance activities and investor relations expenses ; an increase in legal expenses of $

cash flows from operating activities during the year ended december 31 , 2018 , cash used in operating activities was $ 75.5 million , which consisted of a net loss of $ 84.6 million , adjusted by non-cash charges of $ 17.1 million and a net decrease of $ 8.0 million in our operating assets and liabilities . the non-cash charges primarily consisted of $ 16.9 million in stock-based compensation and $ 1.9 million in depreciation and amortization , partially offset by $ 1.7 million in accretion of discounts on our short-term investments . the net decrease in our operating assets and liabilities of $ 8.0 million was primarily attributable to : a net decrease in deferred revenue of $ 38.2 million resulting from the recognition of $ 59.2 million in upfront fees and milestone payments under asc 606 pursuant to our collaboration agreements , offset by the $ 21.0 million ( net of the payment of an associated sublicense fee of $ 4.0 million to sgen ) new milestone addition to deferred revenue in 2018 resulting from the abbvie cx-2029 milestone payment received ; a decrease of $ 4.9 million resulting from the increase in prepaid expenses and other current assets ; partially offset by an increase in cash flows from accounts receivable primarily from the $ 10.0 million we received from bms for achieving the milestone of ind filing of bms-986249 in 2018 ; an increase of $ 24.8 million in accrued liabilities , income tax payable and other long-term liabilities resulting primarily from a $ 13.3 million increase in income tax payable , a


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows from operating activities during the year ended december 31 , 2018 , cash used in operating activities was $ 75.5 million , which consisted of a net loss of $ 84.6 million , adjusted by non-cash charges of $ 17.1 million and a net decrease of $ 8.0 million in our operating assets and liabilities . the non-cash charges primarily consisted of $ 16.9 million in stock-based compensation and $ 1.9 million in depreciation and amortization , partially offset by $ 1.7 million in accretion of discounts on our short-term investments . the net decrease in our operating assets and liabilities of $ 8.0 million was primarily attributable to : a net decrease in deferred revenue of $ 38.2 million resulting from the recognition of $ 59.2 million in upfront fees and milestone payments under asc 606 pursuant to our collaboration agreements , offset by the $ 21.0 million ( net of the payment of an associated sublicense fee of $ 4.0 million to sgen ) new milestone addition to deferred revenue in 2018 resulting from the abbvie cx-2029 milestone payment received ; a decrease of $ 4.9 million resulting from the increase in prepaid expenses and other current assets ; partially offset by an increase in cash flows from accounts receivable primarily from the $ 10.0 million we received from bms for achieving the milestone of ind filing of bms-986249 in 2018 ; an increase of $ 24.8 million in accrued liabilities , income tax payable and other long-term liabilities resulting primarily from a $ 13.3 million increase in income tax payable , a
```    
 Suspicious Activity Report : because our probody therapeutics are designed to minimize binding of potent anti-cancer therapy to normal tissues , we believe we can address a new class of targets with attractive molecular features that were previously unsuitable because of high expression on normal tissues . cd166 is an example of this kind of target . cd166 is highly and homogenously expressed in multiple different tumors types , which makes it an attractive target for a probody drug conjugate therapeutic ; however , the high expression of cd166 on normal tissues makes this a difficult target to drug with a traditional adc . cx-2009 is currently in the dose escalation portion of a phase 1/2 study . in february 2019 , we disclosed initial clinical data on cx-2009 at the cytomx r & d day . in addition to our wholly owned programs , we have entered into several strategic collaborations with leading oncology-focused pharmaceutical companies , such as abbvie inc. , through its subsidiary abbvie ireland unlimited company ( “ abbvie ” ) , amgen , inc. ( “ amgen ” ) and bristol-myers squibb company ( “ bms ” ) . the most advanced program from our partnerships is a bms-986249 , a ctla-4 probody therapeutic , which bms is currently advancing through the dose escalation phase of a phase 1/2 clinical trial . we are also treating patients in a phase 1/2 clinical study for cx-2029 , a pdc targeting the highly expressed target , cd71 that we have partnered with abbvie . we have also extended our probody platform to the t-cell engaging bispecific modality . our most advanced program in that modality is an epidermal growth factor receptor-cd3 ( “ egfr-cd3 ” ) t-cell bispecific , which is currently in lead optimization stage , and which we are developing in partnership with amgen . we currently have three product candidates enrolling patients in clinical trials that we are conducting and one product candidate enrolling patients in clinical trials which our partner , bms , is conducting , but we do not have any product candidates approved for sale , and we continue to incur significant research and development and general administrative expenses related to our operations . we are not profitable and have incurred losses in each year since our founding in 2008. our net loss was $ 84.6 million , $ 43.1 million and $ 58.9 million for 2018 , 2017 and 2016 , respectively . as of december 31 , 2018 and 2017 we had an accumulated deficit of $ 315.0 million and $ 219.5 million , respectively . we expect to continue to incur significant losses for the foreseeable future . 77 regulatory agencies , including the fda , regulate many aspects of a product candidate 's life cycle , including research and development and preclinical and clinical testing . we will need to commit significant time , resources , and funding to develop our wholly owned and partnered product candidates in clinical trials , including cx-072 , cx-2009 and cx-2029 as well as any additional product candidates for which we initiate clinical trials in 201 9 and beyond . we are unable to provide the nature , timing , and estimated costs of the efforts necessary to complete the development of our product candidates because , among other reasons , of regulatory uncertainty , manufacturing limitations and the pace of enrollment of our clinical trials , which is a function of many factors , including the availability and proximity of patients with the relevant condition . we currently have no manufacturing capabilities and do not intend to establish any such capabilities in the near term . as such , we are dependent on third parties to supply our product candidates according to our specifications , in sufficient quantities , on time , in compliance with appropriate regulatory standards and at competitive prices . components of results of operations revenue our revenue to date has been primarily derived from non-refundable license payments , milestone payments and reimbursements for research and development expenses under our research , collaboration , and license agreements . we recognize revenue from upfront payments over the term of our estimated period of performance under the agreement using a cost-based input method or a common measure of progress for the entire performance obligation . in addition to receiving upfront payments , we may also be entitled to milestone and other contingent payments upon achieving predefined objectives . revenue from milestones and other contingent payments , when it is probable that there will not be a significant revenue reversal , is also recognized over the performance period based on a similar method . reimbursements from bms and pfizer for research and development costs incurred under our research , collaboration and license agreements with them are classified as revenue . for the foreseeable future , we do not expect to generate any revenue from the sale of products unless and until such time as our product candidates have advanced through clinical development and obtained regulatory approval . we expect that any revenue we generate in the foreseeable future will fluctuate from year to year as a result of the timing and amount of milestones and other payments from our collaboration agreements with abbvie , amgen , bms , immunogen and any other collaboration partners , and as a result of the fluctuations in the research and development expenses we incur in the performance of assigned activities under these agreements . abbvie ireland unlimited company ( “ abbvie ” ) , one of our collaboration partners , entered into a license agreement with seattle genetics , inc. ( “ sgen ” ) to license certain intellectual property rights . as part of our collaboration agreement with abbvie , we pay sgen sublicense fees . these sublicense fees are treated as reductions to the transaction price and combined with the performance obligation to which they relate . story_separator_special_tag 82 comparison of years ended december 31 , 2017 and 2016 revenue year ended december 31 , 2017 2016 change ( in thousands ) revenue $ 71,623 $ 15,043 $ 56,580 revenue increased $ 56.6 million during the year ended december 31 , 2017 compared to the corresponding period in 2016. the following table summarizes our revenue by collaboration partner during the respective periods : replace_table_token_7_th the increase in revenue from abbvie of $ 16.2 million for the year ended december 31 , 2017 compared to the corresponding period in 2016 was due to recognition of $ 14.0 million , net of the associated sublicense fee , from the milestone payment we received as a result of our achievement of certain milestones required to be met to begin glp toxicology studies under the abbvie agreements , and an increase of $ 2.2 million , net of the related deferred costs , related to the recognition of the upfront payment we received in april 2016. we entered into the amgen agreement in september 2017 and we recognized $ 1.3 million of upfront payments in 2017. the increase in revenue from bms of $ 26.9 million for the year ended december 31 , 2017 compared to the corresponding period in 2016 was due to an increase of $ 17.1 million related to the recognition of an upfront payment we received in connection with the expansion of our collaboration , an increase of $ 2.1 million related to the recognition of payments made in connection with the selection of its fourth target under our collaboration and license agreement with bms and the acceleration of the research timeline triggered by bms 's selection of a fourth target under the bms agreement , and a milestone payment of $ 10.0 million related to the ind filing for bms-986249 by bms in 2017. these increases were partially offset by a milestone payment of $ 2.0 million payment received in 2016 for the selection of bms-986249 clinical candidate , and a decrease of $ 0.3 million related to research and development services provided to bms . the increase in revenue from immunogen of $ 12.5 million for the year ended december 31 , 2017 compared to the corresponding period in 2016 was a result of the recognition of $ 6.6 million for the delivery of the immunogen 2017 license to immunogen in connection with the immunogen research agreement and the recognition of $ 5.9 million resulting from an amendment to the immunogen research amendment . see note 9 - research and collaboration agreements under item 8 of this annual report on form 10-k for more details . the decrease in revenue from pfizer of $ 0.3 million for the year ended december 31 , 2017 compared to the corresponding period in 2016 was due to a reduction in the research and development services we provided to pfizer . in march 2018 , pfizer gave notice terminating our collaboration in its entirety . as a result of such termination , we are no longer eligible to receive any future payments from our collaboration with pfizer . research and development expenses year ended december 31 , 2017 2016 change ( in thousands ) research and development $ 92,277 $ 54,755 $ 37,522 83 research and development expenses increased $ 37.5 million during the year ended december 31 , 2017 compared to the corresponding period in 2016. the increase was primarily attributable to the following : a non-cash charge of $ 10.7 million of in-process research and development expense recognized related to the amgen agreement ; $ 10.0 million sublicense payment made to ucsb triggered by the $ 200.0 million upfront payment made by bms in connection with our expanded collaboration ; $ 2.1 million of ucsb sublicense fees accrued as a result of the amgen agreement ; $ 1.0 million of ucsb sublicense fees recognized for our achievement of certain milestones required to be met to begin glp toxicology studies under the abbvie agreement and the ind filing for bms-986249 by bms ; an increase of $ 8.5 million in pharmacology studies and clinical trial expenses resulting from the advancement of cx-072 , cx-2009 and cx-2029 in 2017 ; an increase of $ 5.3 million in personnel-related expenses and allocation of it and facilities-related expenses due to an increase in headcount ; an increase of $ 1.7 million in consulting expenses due to the commencement of clinical trials in 2017 ; an increase of $ 0.6 million related to expenses incurred in acquiring a patent ; and an increase of $ 0.5 million in stock-based compensation resulting from increased headcount and an increase in the value of our stock . these increases were partially offset by : a decrease of $ 2.1 million in manufacturing expenses for our cx-072 and cx-2009 programs due to manufacturing activities occurring in 2016 in preparation for clinical trials in 2017 ; a decrease in laboratory supply expenses of $ 0.4 million ; and a decrease in program management expenses of $ 0.4 million . the following table summarizes our research and development expenses by program incurred during the respective periods : replace_table_token_8_th general and administrative expenses year ended december 31 , 2017 2016 change ( in thousands ) general and administrative $ 25,605 $ 19,874 $ 5,731 84 general and administrative expense increased $ 5.7 million during the year ended december 31 , 2017 compared to the corresponding period in 2016. the increase was attributable to an increase of $ 1.4 million in personnel-related expenses and an increase of $ 1.0 million in recruitment fees due to an increase in headcount and temporary labor ; an increase in stock-based compensation of $ 1.0 million due to an increase in headcount and an increase in the value of our stock ; an increase of $ 1.2 million in consulting services expenses primarily due to an increase in tax and accounting compliance activities and investor relations expenses ; an increase in legal expenses of $

